TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7992096
Drug: Biotherapy (IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotherapy (IL-2 plus IFN-alpha) administered concurrently with CVD
Study: 27015572
Drug: Subtenon triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subtenon triamcinolone acetonide (TA) injection
Study: 25640290
Drug: Immediate-release tapentadol
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tapentadol
Study: 21209411
Drug: AFQ056 (mGluR5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056 (mGluR5 antagonist)
Study: 17848936
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (160 IU/day, administered four times a day for 8 weeks)
Study: 16403776
Drug: ExGLU (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExGLU (75 g of glucose in 250 ml of water)
Study: 9437565
Drug: Low electrical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low electrical dosage relative to seizure threshold
Study: 9437565
Drug: High electrical
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High electrical dosage relative to seizure threshold
Study: 8267194
Drug: Low-dose naloxone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naloxone (0.5 microgram.kg‐1.min‐1)
Study: 8267194
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone (11.5 micrograms/kg bolus followed by 5 micrograms.kg‐1.min‐1 infusion)
Study: 3545282
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg danazol
Study: 3545282
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg danazol
Study: 3545282
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg danazol
Study: 29655497
Drug: Intraosseous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous regional administration (IORA) of 500 mg vancomycin into the tibia
Study: 29655497
Drug: Systemic intravenous
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic intravenous (IV) administration of 15 mg/kg (maximum of 2 g) vancomycin
Study: 26651278
Drug: Helmetless-tackling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helmetless-tackling intervention (5-minute tackling drill without helmets and shoulder pads, twice per week in preseason and once per week during the season)
Study: 11332932
Drug: Bolus gavage
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus gavage feeding with milk (12 ml kg(‐1) d(‐1) increments, 12 meals per day)
Study: 3198936
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated H1N1 reassortant vaccine
Study: 3198936
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated H3N2 reassortant vaccine
Study: 3198936
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated virus vaccine
Study: 30642381
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine collaborative care (TCMCMC) including standard TCM history taking, physical examination, acupuncture (10 sessions of 30 minutes each), and TCM non-pharmacological advice in addition to usual rheumatologic care.
Study: 28713486
Drug: Concurrent aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent aerobic and resistance training (3 times a week for 16 weeks)
Study: 28713486
Drug: Concurrent aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent aerobic and resistance training
Study: 20031007
Drug: Olopatadine (OLO)
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine (OLO) nasal spray 0.6% (1 or 2 sprays/nostril, b.i.d.)
Study: 20031007
Drug: Olopatadine (OLO)
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine (OLO) nasal spray 0.6% (1 spray/nostril, b.i.d.)
Study: 20031007
Drug: Olopatadine (OLO)
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine (OLO) nasal spray 0.6%
Study: 17916225
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg/day)
Study: 9560030
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at 0.1 IU/kg/d, n=16
Study: 9560030
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at 0.2 IU/kg/d, n=20
Study: 9560030
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment), n=12
Study: 7882702
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg zuclopenthixol
Study: 7882702
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zuclopenthixol
Study: 7882702
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg zuclopenthixol
Study: 7882702
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg to 20 mg daily zuclopenthixol (flexible dosing)
Study: 3065661
Drug: Thymopentin and
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin and Hevac B Pasteur vaccine (3 doses of 5 micrograms s.c. each of vaccine at monthly intervals and 12 doses of 50 mg s.c. of thymopentin on alternate days between the first and the second vaccination)
Study: 3065661
Drug: Hevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac B Pasteur vaccine (3 doses of 5 micrograms s.c. each of vaccine at monthly intervals)
Study: 3065661
Drug: Hevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac B Pasteur vaccine (3 doses of 10 micrograms s.c. each of vaccine at monthly intervals)
Study: 24561548
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg b.d. (with dose reduction to 2.5 mg b.d. for certain patients)
Study: 15625256
Drug: Priming group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming group (rocuronium 0.06 mg x kg(‐1) followed by 0.54 mg x kg(‐1) three minutes later)
Study: 15625256
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (rocuronium 0.6 mg x kg(‐1))
Study: 11786451
Drug: Aspirin (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75-150 mg daily)
Study: 11786451
Drug: Intravenous glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycoprotein IIb/IIIa antagonist added to aspirin
Study: 10468203
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1200 mg twice daily
Study: 10468203
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1800 mg thrice daily
Study: 10468203
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (combined ALA groups)
Study: 7618455
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg, single oral dose)
Study: 7618455
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg, single oral dose)
Study: 2756910
Drug: Carbohydrate infusion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate infusion
Study: 2756910
Drug: Protein infusion
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein infusion
Study: 2756910
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal infusion
Study: 2756910
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution
Study: 27701428
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (2 g per day for 30 days)
Study: 18799080
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) treatment (20 microg-40 microg-60 microg) administered via intravenous infusion for 3 consecutive days
Study: 14516802
Drug: Atropine treatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine treatment followed by plano lens for sound eye
Study: 14516802
Drug: Atropine treatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine treatment alone
Study: 14516802
Drug: Atropine treatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine treatment with plano lens
Study: 10656435
Drug: Exisulind 400
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 400 mg p.o. twice a day
Study: 10656435
Drug: Exisulind 300
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 300 mg p.o. twice a day
Study: 10656435
Drug: Exisulind 200
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 200 mg p.o. twice a day
Study: 10656435
Drug: Exisulind (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind (all doses)
Study: 9582639
Drug: Fixed appliance
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliance therapy (non-extraction)
Study: 9582639
Drug: Fixed appliance
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliance therapy (extraction)
Study: 9582639
Drug: Fixed appliance
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliance therapy (both groups)
Study: 3777409
Drug: Nalbuphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 5 mg after fentanyl
Study: 3777409
Drug: Nalbuphine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (all doses) after fentanyl
Study: 29183872
Drug: Low-dose endotoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose endotoxin challenge in lean men
Study: 27235530
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of parathyroid hormone (PTH) for six weeks
Study: 20528001
Drug: AZD0837 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 intravenous infusion
Study: 3046820
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mixed gangliosides (Cronassial) every weekday intramuscularly for 3-4 months
Study: 3046820
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mixed gangliosides (Cronassial) after 13-19 weeks
Study: 3046820
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mixed gangliosides (Cronassial) after greater than 20 weeks
Study: 3046820
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 3 months
Study: 352763
Drug: unspecific cream
Normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: unspecific cream vehicle without active agent
Study: 352763
Drug: unspecific vehicle
Normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: unspecific vehicle for clindamycin treatment
Study: 28429905
Drug: 25,000 IU/4-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25,000 IU/4-weekly cholecalciferol (Group A)
Study: 28429905
Drug: 50,000 IU/4-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU/4-weekly cholecalciferol (Group B)
Study: 28429905
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (25,000 IU and 50,000 IU)
Study: 25566749
Drug: Single rhTSH
Normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single rhTSH administration after two weeks of T3 therapy followed by one week of THW (Group I)
Study: 25566749
Drug: Standard stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard stimulating protocol via rhTSH injections for two consecutive days (Group II)
Study: 24236673
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (four most commonly prescribed)
Study: 21208151
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl ODT
Study: 17848873
Drug: Caffeine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (oral and intravenous) for PDPH prophylaxis
Study: 17848873
Drug: Caffeine (oral)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (oral) for PDPH treatment
Study: 17848873
Drug: Caffeine (IV)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (IV) for PDPH treatment (from quasirandomized and open-label trials)
Study: 17848873
Drug: Caffeine as
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine as an antinociceptive agent for PDPH
Study: 8090093
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at L2/3 over 15 sec
Study: 8090093
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at L4/5 over 15 sec
Study: 8090093
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at L2/3 over 30 sec
Study: 3407611
Drug: 170 mg
Normalized name: mannitol 170 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 170 mg alpha‐tocopherol acetate
Study: 27299514
Drug: Active Bright
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Bright Light Therapy (BLT) at 10,000 lux for 45 minutes daily for 2 weeks
Study: 27299514
Drug: Control Bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Bright Light Therapy (BLT) at approx. 100 lux for 45 minutes daily for 2 weeks
Study: 26591394
Drug: Combined aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined aspirin and dipyridamole
Study: 23034468
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg with candesartan 8 mg
Study: 23034468
Drug: Chlorthalidone (CTD)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (CTD) 12.5 mg with candesartan 8 mg
Study: 9495423
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral placebo and i.m. midazolam and atropine)
Study: 3289837
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy alone (group 1)
Study: 26060295
Drug: Maraviroc (MVC)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc (MVC) 150 mg once daily
Study: 29933096
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Study: 16675499
Drug: Leg exercise
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leg exercise (L) in upright position
Study: 16675499
Drug: Combined arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined arm and leg exercise (A + L) in upright position
Study: 16675499
Drug: Combined arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined arm and leg exercise (A + L) in supine position
Study: 15517300
Drug: Infliximab, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab, 5 mg/kg at week 0/2/6, followed by 5 mg/kg every 6 weeks in an open study.
Study: 11181366
Drug: Ethionamide (ETA)
Normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide (ETA) administered with orange juice
Study: 11181366
Drug: Ethionamide (ETA)
Normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide (ETA) administered with food
Study: 11181366
Drug: Ethionamide (ETA)
Normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide (ETA) administered with antacids
Study: 11181366
Drug: Ethionamide (ETA)
Normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide (ETA) administered on an empty stomach (reference)
Study: 9310718
Drug: Fluorescence technique
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescence technique for teaching application of protective creams
Study: 9310718
Drug: Instructive videotape
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructive videotape for teaching application of protective creams
Study: 8257616
Drug: Cholesterol-lowering drug
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering drug use at follow-up
Study: 24858566
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV) administered intranasally at doses of 1×10(5), 1×10(6), or 1×10(7) TCID50
Study: 24858566
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV) administered intranasally
Study: 21981973
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (IST) during hospitalization
Study: 21981973
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (IST) continued after discharge
Study: 19682735
Drug: Non-invasive ventilation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive ventilation as rescue therapy
Study: 17403946
Drug: Thalidomide in
Normalized name: Product containing thalidomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide in combination with dexamethasone
Study: 11950491
Drug: MPA at
Normalized name: crospovidone (15 mpa.s at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA at dose of 2.5 mg daily (group A)
Study: 11950491
Drug: MPA at
Normalized name: crospovidone (15 mpa.s at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA at dose of 5 mg daily (group B)
Study: 9798809
Drug: Oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pantoprazole 40 mg
Study: 1996436
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (Imferon; Fisons) - usual recommended dose
Study: 1996436
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (Imferon; Fisons) - two-thirds of the recommended dose
Study: 1996436
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (Imferon; Fisons) - both doses
Study: 6394350
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg/day (Group A)
Study: 6394350
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg/day (Group B)
Study: 6394350
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release nifedipine 20 mg/day (Group C)
Study: 20977576
Drug: Exenatide twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice-daily
Study: 18423812
Drug: Triple RAAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple RAAS blockade (spironolactone 25 mg)
Study: 18423812
Drug: Double RAAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double RAAS blockade (cilazapril 5 mg, telmisartan 80 mg, hydrochlorothiazide 12.5 mg)
Study: 10080412
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 to 50 mg twice daily
Study: 10080412
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 to 100 mg twice daily
Study: 10080412
Drug: Carvedilol and
Normalized name: carvedilol and ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol and Metoprolol (both low dose/high dose)
Study: 8006281
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus aspirin (150 mg once daily)
Study: 8006281
Drug: Preadmission therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preadmission therapy with aspirin
Study: 23767174
Drug: Propofol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (100 mg/kg/min) with remifentanil (0.25 mg/kg/min)
Study: 23767174
Drug: Isoflurane (0.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane (0.8% end‐tidal) with remifentanil (0.25 mg/kg/min)